Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study

NCT02636426 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
17
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Amsterdam UMC, location VUmc